United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva - tenofovir disoproxil fumarate; emtricitabine - tablet - 245mg ; 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk - tenofovir disoproxil fumarate; emtricitabine - tablet - 245mg ; 200mg

Malta - English - Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - emtricitabine, tenofovir disoproxil - film-coated tablet - emtricitabine 200 mg tenofovir disoproxil 245 mg - antivirals for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - emtricitabine, quantity: 200 mg; tenofovir alafenamide fumarate, quantity: 11.2 mg (equivalent: tenofovir alafenamide, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; iron oxide black - treatment of hiv-1 infection: descovy is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25kg. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of descovy (see section 5.1 pharmacodynamic properties).,hiv-1 pre-exposure prophylaxis: descovy is indicated for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in at-risk adults and adolescents weighing at least 35 kg, excluding individuals at risk from receptive vaginal sex.

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - emtricitabine, quantity: 200 mg; tenofovir alafenamide fumarate, quantity: 28 mg (equivalent: tenofovir alafenamide, qty 25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - treatment of hiv-1 infection: descovy is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25kg. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of descovy (see section 5.1 pharmacodynamic properties).,hiv-1 pre-exposure prophylaxis: descovy is indicated for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in at-risk adults and adolescents weighing at least 35 kg, excluding individuals at risk from receptive vaginal sex.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - truvada ® , a combination of emtriva ® and viread ® , is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 17 kg [see dosage and administration (2) and clinical studies (14)] . the following points should be considered when initiating therapy with truvada for the treatment of hiv-1 infection:the following points should be considered when initiating therapy with truvada for the treatment of hiv-1 infection: - it is not recommended that truvada be used as a component of a triple nucleoside regimen. - truvada should not be coadministered with atripla ® , complera ® , emtriva, genvoya ® , odefsey ® , stribild ® , viread or lamivudine-containing products [see warnings and preca

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - truvada® , a combination of emtriva® and viread® , is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 17 kg [see dosage and administration (2) and clinical studies (14)] . the following points should be considered when initiating therapy with truvada for the treatment of hiv-1 infection: - it is not recommended that truvada be used as a component of a triple nucleoside regimen. - truvada should not be coadministered with atripla® , complera® , emtriva, genvoya® , odefsey® , stribild® , viread or lamivudine-containing products [see warnings and precautions (5.4)] . - in treatment experienced patients, the use of truvada should be guided by laboratory testing and treatment history [see microbiology (12.4)] . truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trial

United States - English - NLM (National Library of Medicine)

direct rx - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - 1.1 treatment of hiv-1 infection truvada®, a combination of emtriva® and viread®, is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 17 kg [see dosage and administration (2) and clinical studies (14)]. the following points should be considered when initiating therapy with truvada for the treatment of hiv-1 infection: it is not recommended that truvada be used as a component of a triple nucleoside regimen. truvada should not be coadministered with atripla®, complera®, emtriva, genvoya®, odefsey®, stribild®, viread or lamivudine-containing products [see warnings and precautions (5.4)]. in treatment experienced patients, the use of truvada should be guided by laboratory testing and treatment history [see microbiology (12.4)]. 1.2 pre-exposure prophylaxis truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults a

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - 1.1 treatment of hiv-1 infection truvada®, a combination of emtriva® and viread®, is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 17 kg [see dosage and administration (2) and clinical studies (14)]. the following points should be considered when initiating therapy with truvada for the treatment of hiv-1 infection: it is not recommended that truvada be used as a component of a triple nucleoside regimen. truvada should not be coadministered with atripla®, complera®, descovy®, emtriva, genvoya®, odefsey®, stribild®, vemlidy®, viread, or lamivudine-containing products [see warnings and precautions (5.4)]. in treatment experienced patients, the use of truvada should be guided by laboratory testing and treatment history [see microbiology (12.4)]. 1.2 pre-exposure prophylaxis truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acqui

Israel - English - Ministry of Health

gilead sciences israel ltd - cobicistate; elvitegravir; emtricitabine; tenofovir alafenamide - film coated tablets - tenofovir alafenamide 10 mg; emtricitabine 200 mg; cobicistate 150 mg; elvitegravir 150 mg - emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat - gendevra is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir as follows:• in adults and adolescents aged from 12 years and with body weight at least 35 kg• in children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.תוספת התוויה: 2/7/2019addition of new info to posology section: precaution in pregnant women